{"mainPropery":{"diseaseId":12128,"diseaseName":"Methylmalonic acidemia with homocystinuria type cblC","hasGardWebPage":false,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/12128/methylmalonic-acidemia-with-homocystinuria-type-cblc","synonyms":["Methylmalonic acidemia and homocystinuria cblc","Cobalamin C disease","cblC","Methylmalonic aciduria and homocystinuria cblc","Methylmalonic aciduria and homocystinuria, cblC type "],"synonyms-with-source":[{"name":"Methylmalonic acidemia and homocystinuria cblc","source":""},{"name":"Cobalamin C disease","source":""},{"name":"cblC","source":""},{"name":"Methylmalonic aciduria and homocystinuria cblc","source":""},{"name":"Methylmalonic aciduria and homocystinuria, cblC type ","source":"OMIM"}],"identifiers":[{"identifierType":"OMIM","identifierId":"277400"},{"identifierType":"ORPHANET","identifierId":"79282"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":138,"resourceName":"Metabolic Support UK","abbreviation":"","address1":"5 Hilliards Court","address2":"Sandpiper Way","address3":"Chester Business Park","address4":"","address5":"","city":"Chester","state":"","zip":"CH4 9QP","country":"United Kingdom","phone":"0845 241 2173","tty":"","tollFree":"0800 652 3181 ","fax":"","email":"https://www.metabolicsupportuk.org/contact-us","url":"https://www.metabolicsupportuk.org","freeText":""},{"resourceID":221,"resourceName":"Organic Acidemia Association","abbreviation":"","address1":"9040 Duluth Street","address2":"","address3":"","address4":"","address5":"","city":"Golden Valley","state":"MN","zip":"55427","country":"United States","phone":"763-559-1797","tty":"","tollFree":"","fax":"866-539-4060","email":"mkstagni@gmail.com","url":"http://www.oaanews.org/","freeText":""},{"resourceID":3595,"resourceName":"HCU Network America","abbreviation":"","address1":"623 Creek Lane","address2":"","address3":"","address4":"","address5":"","city":"Flourtown","state":"PA","zip":"19031","country":"United States","phone":"630-360-2087","tty":"","tollFree":"","fax":"","email":"info@hcunetworkamerica.org","url":"http://hcunetworkamerica.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/277400' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed/?term=%28%28%22vitamin%20b%2012%22[MeSH%20Terms]%20OR%20%22vitamin%20b%2012%22[All%20Fields]%20OR%20%22cobalamin%22[All%20Fields]%29%20AND%20C[All%20Fields]%20AND%20%28%22disease%22[MeSH%20Terms]%20OR%20%22disease%22[All%20Fields]%29%29%20OR%20%28%22Methylmalonic%20acidemia%20with%20homocystinuria%22[Supplementary%20Concept]%20OR%20%22Methylmalonic%20acidemia%20with%20homocystinuria%22[All%20Fields]%20OR%20%22methylmalonic%20acidemia%20with%20homocystinuria%22[All%20Fields]%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Methylmalonic acidemia with homocystinuria type cblC. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/methylmalonic-acidemia-with-homocystinuria' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Methylmalonic acidemia with homocystinuria type cblC. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":350,"resourceId":1167,"resourceName":"Baby's First Test","descriptionText":"<a href='https://www.babysfirsttest.org/newborn-screening/conditions/methylmalonic-acidemia-with-homocystinuria' target='_blank'>Baby's First Test</a> is the nation's newborn screening education center for families and providers. This site provides information and resources about screening at the local, state, and national levels and serves as the Clearinghouse for newborn screening information.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79282' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1328/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1547,"resourceId":2175,"resourceName":"Screening, Technology And Research in Genetics (STAR-G) Project","descriptionText":"The <a href='http://www.newbornscreening.info/Parents/organicaciddisorders/MMA_HCU.html' target='_blank'>Screening, Technology And Research in Genetics (STAR-G) Project</a> has a fact sheet on this condition, which was written specifically for families that have received a diagnosis as a result of newborn screening. This fact sheet provides general information about the condition and answers questions that are of particular concern to parents.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:277400' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":7563,"questionText":"What is methylmalonic acidemia with homocystinuria cblC type?","answerText":"<strong>Methylmalonic academia with homocystinuria (MMA+HCU) cblC</strong> is a genetic disorder that prevents the body from breaking down certain amino acids found in protein (i.e., isoleucine, valine, methionine, and threonine). As a result, homocystine, methylmalonic acid, and other harmful substances build-up in the body. Treatment should begin as soon as possible. In general, treatment may involve a low-protein diet, medical formula/drink, regular meals, careful monitoring, and vitamin B12 shots. Most US states now offer newborn screening for MMA+HCU, allowing for early detection and treatment. However even with early treatment, most children with MMA+HCU experience some symptoms affecting vision, growth, and learning. MMA+HCU cblC type is caused by changes in the <em><a target=\"_blank\" href=\"http://ghr.nlm.nih.gov/gene/MMACHC\">MMACHC</a></em> gene. It is inherited in an <a target=\"_blank\" href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\">autosomal recessive</a> fashion.[7470]","dateModified":"2014-06-11T12:22:00"},"basicQuestions":[{"questionId":7565,"questionText":"What is the best case scenario with symptoms? Is cobalamin-C better or worse than methylmalonic acidemia?","answerText":"For both methylmalonic acidemia and methylmalonic acidemia with homocystinuria (MMA+HCU) cblC type signs and symptoms can vary from mild to\r\nlife-threatening. There have been cases of MMA+HCU cblC type associated with mild symptoms and delayed age at onset (teen to adult years). In most cases however, signs and symptoms of MMA+HCU cblC type present in infancy. Even with early diagnosis and treatment, children with the condition tend to have symptoms affecting vision, growth, and learning. <br />\r\n<br />\r\nA recent study of 12 children with early onset MMA+HCU CblC type, diagnosed by newborn screening, and treated early with intramuscular hydroxocobalamin, oral betaine, folinic acid, l-carnitine, and dietary protein modification were reported to have developed the following symptoms:<br />\r\n<br />\r\nMild to moderate low muscle tone (91%)<br />\r\nQuick uncontrollable movements of the eye (<a target=\"_blank\" href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003037.htm\">nystagmus)</a> with variable affect on vision (75%)<br />\r\nSeizure (25%)<br />\r\nSmall head circumference (17%)<br />\r\n<br />\r\n​Testing of communication, socialization, daily living skills, motor skills, and behavior showed mild to moderate delays in these areas for most children. Socialization was the least affected aspect of development.[7471]","dateModified":"2014-06-11T12:23:00","resourceClassificationName":"Symptoms","references":[{"referenceId":7471,"authors":"Weisfeld-Adams JD, Bender HA, Miley-Åkerstedt A, Frempong T, Schrager NL, Patel K, Naidich TP, Stein V, Spat J, Towns S, Wasserstein MP, Peter I, Frank Y,  Diaz GA","articleTitle":"Neurologic and neurodevelopmental phenotypes in young children with early-treated combined methylmalonic acidemia and homocystinuria, cobalamin C type","bookWebsiteJournalTitle":"Mol Genet Metab","date":"November 2013","volume":"110(3)","pages":"241-7","url":"http://www.ncbi.nlm.nih.gov/pubmed/23954310","dateAccessed":"2014-06-11T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7564,"questionText":"What is the life expectancy of people with methylmalonic acidemia with homocystinuria cblC type?","answerText":"The effects of methylmalonic acidemia with homocystinuria (MMA+HCU) cblC type vary from mild to\r\nlife-threatening. As a result, life expectancy can vary greatly among people with this condition. Your child's doctors are best suited to counsel you regarding the severity of your child's condition and overall prognosis. People with MMA+HCU are at risk for serious health complications, particularly if their body becomes over-stressed by illness or other physical stress. While we are not aware of life expectancy statistics specifically for MMA+HCU cblC, we have developed a Q&amp;A on life-expectancy for methylmalonic acidemia in general, which you may find helpful. You can view this Q&amp;A at the following link:<br />\r\n<a target=\"_blank\" href=\"http://rarediseases.info.nih.gov/gard/7033/methylmalonic-acidemia/case/35540/case-questions \">http://rarediseases.info.nih.gov/gard/7033/methylmalonic-acidemia/case/35540/case-questions </a>","dateModified":"2014-06-11T12:23:00","resourceClassificationName":"Prognosis","references":[]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":3579,"relatedDiseaseName":"Methylmalonic acidemia with homocystinuria","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":46013,"abbreviatedInquiry":"How long do people live on average with cobalamin-C? What is the best case scenario with symptoms? Is cobalamin-C better or worse than methylmalonic acidemia? My baby failed her newborn screen. We are awaiting her final test results, but the doctor says it is probably cobalamin-C. ","caseQuestions":[{"questionId":7563,"questionText":"What is methylmalonic acidemia with homocystinuria cblC type?","answerText":"<strong>Methylmalonic academia with homocystinuria (MMA+HCU) cblC</strong> is a genetic disorder that prevents the body from breaking down certain amino acids found in protein (i.e., isoleucine, valine, methionine, and threonine). As a result, homocystine, methylmalonic acid, and other harmful substances build-up in the body. Treatment should begin as soon as possible. In general, treatment may involve a low-protein diet, medical formula/drink, regular meals, careful monitoring, and vitamin B12 shots. Most US states now offer newborn screening for MMA+HCU, allowing for early detection and treatment. However even with early treatment, most children with MMA+HCU experience some symptoms affecting vision, growth, and learning. MMA+HCU cblC type is caused by changes in the <em><a target=\"_blank\" href=\"http://ghr.nlm.nih.gov/gene/MMACHC\">MMACHC</a></em> gene. It is inherited in an <a target=\"_blank\" href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\">autosomal recessive</a> fashion.[7470]","dateModified":"2014-06-11T12:22:00","references":[{"referenceId":7470,"authors":"","articleTitle":"Methylmalonic Acidemia with Homocystinuria","bookWebsiteJournalTitle":"Screening, Technology and Research in Genetics (STAR-G)","date":"","volume":"","pages":"","url":"http://www.newbornscreening.info/Parents/organicaciddisorders/MMA_HCU.html","dateAccessed":"2014-06-11T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7564,"questionText":"What is the life expectancy of people with methylmalonic acidemia with homocystinuria cblC type?","answerText":"The effects of methylmalonic acidemia with homocystinuria (MMA+HCU) cblC type vary from mild to\r\nlife-threatening. As a result, life expectancy can vary greatly among people with this condition. Your child's doctors are best suited to counsel you regarding the severity of your child's condition and overall prognosis. People with MMA+HCU are at risk for serious health complications, particularly if their body becomes over-stressed by illness or other physical stress. While we are not aware of life expectancy statistics specifically for MMA+HCU cblC, we have developed a Q&amp;A on life-expectancy for methylmalonic acidemia in general, which you may find helpful. You can view this Q&amp;A at the following link:<br />\r\n<a target=\"_blank\" href=\"http://rarediseases.info.nih.gov/gard/7033/methylmalonic-acidemia/case/35540/case-questions \">http://rarediseases.info.nih.gov/gard/7033/methylmalonic-acidemia/case/35540/case-questions </a>","dateModified":"2014-06-11T12:23:00","resourceClassificationName":"Prognosis","references":[]},{"questionId":7565,"questionText":"What is the best case scenario with symptoms? Is cobalamin-C better or worse than methylmalonic acidemia?","answerText":"For both methylmalonic acidemia and methylmalonic acidemia with homocystinuria (MMA+HCU) cblC type signs and symptoms can vary from mild to\r\nlife-threatening. There have been cases of MMA+HCU cblC type associated with mild symptoms and delayed age at onset (teen to adult years). In most cases however, signs and symptoms of MMA+HCU cblC type present in infancy. Even with early diagnosis and treatment, children with the condition tend to have symptoms affecting vision, growth, and learning. <br />\r\n<br />\r\nA recent study of 12 children with early onset MMA+HCU CblC type, diagnosed by newborn screening, and treated early with intramuscular hydroxocobalamin, oral betaine, folinic acid, l-carnitine, and dietary protein modification were reported to have developed the following symptoms:<br />\r\n<br />\r\nMild to moderate low muscle tone (91%)<br />\r\nQuick uncontrollable movements of the eye (<a target=\"_blank\" href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003037.htm\">nystagmus)</a> with variable affect on vision (75%)<br />\r\nSeizure (25%)<br />\r\nSmall head circumference (17%)<br />\r\n<br />\r\n​Testing of communication, socialization, daily living skills, motor skills, and behavior showed mild to moderate delays in these areas for most children. Socialization was the least affected aspect of development.[7471]","dateModified":"2014-06-11T12:23:00","resourceClassificationName":"Symptoms","references":[{"referenceId":7471,"authors":"Weisfeld-Adams JD, Bender HA, Miley-Åkerstedt A, Frempong T, Schrager NL, Patel K, Naidich TP, Stein V, Spat J, Towns S, Wasserstein MP, Peter I, Frank Y,  Diaz GA","articleTitle":"Neurologic and neurodevelopmental phenotypes in young children with early-treated combined methylmalonic acidemia and homocystinuria, cobalamin C type","bookWebsiteJournalTitle":"Mol Genet Metab","date":"November 2013","volume":"110(3)","pages":"241-7","url":"http://www.ncbi.nlm.nih.gov/pubmed/23954310","dateAccessed":"2014-06-11T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13430,"phenoTypeName":"Anorexia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4081,"phenoTypeName":"Failure to thrive","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9825,"phenoTypeName":"Hydrocephalus","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8721,"phenoTypeName":"Lethargy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13085,"phenoTypeName":"Megaloblastic bone marrow","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9844,"phenoTypeName":"Microcephaly","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8266,"phenoTypeName":"Pallor","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10492,"phenoTypeName":"Retinopathy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6245,"phenoTypeName":"Infantile onset","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13705,"phenoTypeName":"Abnormality of extrapyramidal motor function","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":13743,"phenoTypeName":"Cerebral cortical atrophy","percentRanges":"-"},{"phenoTypeId":10972,"phenoTypeName":"Cystathioninemia","percentRanges":"-"},{"phenoTypeId":14591,"phenoTypeName":"Cystathioninuria","percentRanges":"-"},{"phenoTypeId":14585,"phenoTypeName":"Decreased adenosylcobalamin","percentRanges":"-"},{"phenoTypeId":13621,"phenoTypeName":"Decreased methionine synthase activity","percentRanges":"-"},{"phenoTypeId":14523,"phenoTypeName":"Decreased methylcobalamin","percentRanges":"-"},{"phenoTypeId":14514,"phenoTypeName":"Decreased methylmalonyl-CoA mutase activity","percentRanges":"-"},{"phenoTypeId":675,"phenoTypeName":"Delirium","percentRanges":"-"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","percentRanges":"-"},{"phenoTypeId":3410,"phenoTypeName":"Feeding difficulties in infancy","percentRanges":"-"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","percentRanges":"-"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","percentRanges":"-"},{"phenoTypeId":14161,"phenoTypeName":"Hematuria","percentRanges":"-"},{"phenoTypeId":15044,"phenoTypeName":"Hemolytic-uremic syndrome","percentRanges":"-"},{"phenoTypeId":10428,"phenoTypeName":"High forehead","percentRanges":"-"},{"phenoTypeId":13835,"phenoTypeName":"Homocystinuria","percentRanges":"-"},{"phenoTypeId":13836,"phenoTypeName":"Hyperhomocystinemia","percentRanges":"-"},{"phenoTypeId":5248,"phenoTypeName":"Hypomethioninemia","percentRanges":"-"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","percentRanges":"-"},{"phenoTypeId":9870,"phenoTypeName":"Long face","percentRanges":"-"},{"phenoTypeId":11305,"phenoTypeName":"Low-set ears","percentRanges":"-"},{"phenoTypeId":11332,"phenoTypeName":"Macrotia","percentRanges":"-"},{"phenoTypeId":15527,"phenoTypeName":"Megaloblastic anemia","percentRanges":"-"},{"phenoTypeId":13040,"phenoTypeName":"Metabolic acidosis","percentRanges":"-"},{"phenoTypeId":4320,"phenoTypeName":"Methylmalonic acidemia","percentRanges":"-"},{"phenoTypeId":2725,"phenoTypeName":"Methylmalonic aciduria","percentRanges":"-"},{"phenoTypeId":8716,"phenoTypeName":"Muscular hypotonia","percentRanges":"-"},{"phenoTypeId":10043,"phenoTypeName":"Nephropathy","percentRanges":"-"},{"phenoTypeId":15514,"phenoTypeName":"Neutropenia","percentRanges":"-"},{"phenoTypeId":10109,"phenoTypeName":"Nystagmus","percentRanges":"-"},{"phenoTypeId":9805,"phenoTypeName":"Pigmentary retinopathy","percentRanges":"-"},{"phenoTypeId":10031,"phenoTypeName":"Proteinuria","percentRanges":"-"},{"phenoTypeId":10515,"phenoTypeName":"Reduced visual acuity","percentRanges":"-"},{"phenoTypeId":10015,"phenoTypeName":"Renal insufficiency","percentRanges":"-"},{"phenoTypeId":10390,"phenoTypeName":"Smooth philtrum","percentRanges":"-"},{"phenoTypeId":15512,"phenoTypeName":"Thrombocytopenia","percentRanges":"-"},{"phenoTypeId":15543,"phenoTypeName":"Thromboembolism","percentRanges":"-"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","percentRanges":"-"},{"phenoTypeId":5614,"phenoTypeName":"Visual impairment","percentRanges":"-"}],"medicalProducts":[{"productId":286,"genericName":"Betaine","tradeName":"Cystadane","tradeLink":"http://www.cystadane.com/","manufacturer":"","sponsor":"Orphan Europe SARL","indication":"Treatment of homocystinuria to decrease elevated homocysteine blood levels.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/107-43-7","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a608012.html"}],"EncodedName":"Methylmalonic_acidemia_with_homocystinuria_type_cblC"}